Kerry’s Small Business Grant

Senators Kerry and Daschle have introduced a Bill in the Senate (S.1886) that includes a “Small Business Foreign Patent Protection Grant Fund.” The fund is intended provide funds to small businesses who are hoping to file foreign patent applications.

To help small manufacturers and small R&D firms, we need to reduce trade barriers, so that they are able to sell their products and technologies in other countries. Small-business owners commonly cited the expense required to secure foreign patent protection as a significant barrier to their ability to operate in international markets. Part of encouraging the spread of their innovations into other countries is decreasing their vulnerability to big foreign corporations that can take their ideas when they try to sell their products around the world. Our small businesses need patent protection. However, the costs associated with filing such patents are often prohibitively expensive.

(Link to Kerry’s speech discussing the Bill).

Golf Tee Inventor


Patently Absurd discusses several of Arthur Pedrick’s inventions including the following:

UK Patent No. GB1251780. A practice golf tee. Photocells monitor the path of the club head. If they detect that the player is about to hook or slice the ball, a puff of compressed air passes along the conduit 1″ and up the middle of the tee. This blows the ball off the tee so that the player misses it, and does not have to search for a lost ball.

(Thanks to BoingBoing for the link)

img001
Update: Pedrick’s invention is an improvement on George Grant’s 1899 invention of the golf tee.

Orphan Drug Act

The Orphan Drug Act provides market incentives to develop new therapeutics for diseases affecting relatively small numbers of persons. (Providing a seven year period of market exclusivity.) The act applies specifically to therapies for treating diseases or conditions which affect less than 200,000 or affects more than 200,000 persons but for which there is no reasonable expectation that the costs of developing the drug will be recovered from U.S. sales of the drug.

One problem for the FDA has been determining whether the market exclusivity should apply for new entrants who produce a slightly different drug or who treat a slightly different condition.

Robert Bohrer argues (txt)(pdf) that, in the case of monoclonal antibody drugs, the approach to orphan drug exclusivity should be for the FDA to presume antibodies to the same antigen, of the same immunoglobin class and with the same mechanism of action to be the same drug unless the second antibody is shown to be clinically superior to the first.

David Rohde agrees (pdf) that the Act has had a great impact on the development of drugs for treating rare diseases. According to David, “ten times the number of orphan products were approved in the decade following the Act than in the decade preceding Act.”

Weekly Thank You

It is time for my weekly thank you for those who have helped with the weblog.

Matthew Homan almost went overboard with his glowing review of Patently-O. Matthew runs a great site, and it is easy to pick up practice tips from his writings. BoleyBlogs also found a couple of selling points for Patently-O. Nipper provided a link to my 102(f)/103 legislative coverage. Phil McGarrigle provided some insight into the new legislation. Professor Joseph Miller provided an update on his future patent research. Howard Bashman and Martin Schwimmer enjoyed the images of Patently-O. BTW, all the images are cut from patent documents. Kevin Heller also linked in.

Patent Reform

According to Susan Kuchinskas at internetnews.com, business leaders have begun meeting to solve “problems at the USPTO.” IT companies feel that patent quality has dropped as the number of applications has increased. Cisco, Intel, eBay, Symantec, Chiron, Microsoft, and Genentech said they will work with regulators and legislators on patent reform. Susan’s reports come from yesterday and today’s patent reform conference. Elizabeth Miles at Berkeley IPlog has a nice review of the conference. Elizabeth may have more on the conference tomorrow.

Update: Brian Carver presents an insightful look at day two of the conference.

Patent Law Hypothetical: Answer 1

Answer to Question 1:

Generally, 35 U.S.C. §102 is the starting point for determining whether an invention is patentable. In this case, however, nothing in §102 bars patentability: §102(a) cannot block the patent because the goo-whiz was not known before GooCo came up with it. Goo-whiz came on the market less than one year ago, so no §102(b) bar. Goo-whiz was not abandoned under §102(c). The invention was not patented prior to filing a US application under §102(d). §102(e) only applies to prior U.S. applications or “international” applications, not to a nationally filed UK patent. Goo-whiz is not a derivative work under §102(f). And, there is no race to the patent office under §102(g).

The major loss of rights for GooCo is that it will no longer be able to claim a right of priority to the earlier UK application under 35 U.S.C. §119.

Disclaimer.

Claim Drafting Tips

George Wheeler has published an article (pdf) that should be read by anyone and everyone doing prosecution work. Unlike most law review articles, the prose is easy to read and the advice is practical.

Here are some of George’s tips:

1. Write claims that will be literally infringed.
2. Do not rely on means-plus-function claims.
3. Write the specification expansively.
4. Claim in a circle, not a chain.
5. The Examiner is never wrong.
6. Cite the MPEP, not case law.
7. Do not add unnecessary claim limitations.
8. Do not write your opponents’ trial exhibits.
9. Do not just obtain a patent, build a patent position.

Update (April 19, 2004) Read Judge Paul Michel’s claim drafting tips or tips on drafting claims from About.com.

USPTO: Behind the Scenes

Scott Wolinsky has written an enlightening (if cynical) article about the patenting process. According to Scott, successfull prosecution of a patent application requires a novel invention, adequate prosecution skills, and also a bit of luck. Primarily Wolinski finds that the luck is getting the right examiner. (Thanks to Slashdot for the link.)

Professor Lichtman (UChicago) has a nice article (pdf) about this topic and its consequences for prosecution history estoppel. If the patent prosecution process truly has such a significant luck component, then the quality of the examination might need to become an issue when determining validity during litigation. Karl Lenz and Axel Horns discuss the purpose of the patent system (focusing mainly on software patenting).

Ice Cream Cone Inventors


The waffle ice-cream cone is approaching its 100th birthday. (Chicago Tribune). Popular legend is that the first waffle cone was developed at the 1904 World’s Fair in St. Louis. A New York vendor, however, obtained a patent in 1903 on an apparatus for making waffle ice-cream cups. (U.S. Patent 746,971). More Recently, Heinrich Herting patented an ice-cream cone with an edible logo (U.S. Patent 4,859,476). Because of a spike in the prices of butter, chocolate, and vanilla, ice-cream is expected to be expensive this summer. (The Slate)

Patent Law Hypothetical

Question 1:

GooCo filed a patent application for goo-whiz in the UK patent office 14 months ago. (Goo-whiz is a material that is useful as both a leak-stopper and an ice-cream topping.) The UK application is still pending and has not published yet. GooCo began selling the patent-pending product 6 months ago.

GooCo now wants to file for a U.S. Patent. Can it do so? (email) The answer will post tomorrow.

Litigation Bounty

Joseph Miller has a new article (pdf) discussing incentives in patent infringement litigation.

A patent challenger who succeeds in defeating a patent wins spoils that it must share with the world, including all its competitors. This forced sharing undercuts an alleged infringer’s incentive to stay in the fight to the finish – especially if the patent owner offers an attractive settlement. Too many settlements, and too few definitive patent challenges, are the result.

Miller suggests that a litigation bounty delivered to the defendant could offset for the free-riding problem. In a further paper, Miller plans to expand his proposal to include a “patent attack bloc” that could allow defendants to better pool resources and rewards.

Sierra Applied Sciences v. Advanced Energy Ind.

Sierra Applied Sciences, Inc. v. Advanced Energy Ind. (AEI) (Fed. Cir. 2004)
Patent Image
Sierra designed and tested a power supply that arguably infringes AEI’s Patents. (E.g., U.S. Patent 6,001,224). Sierra filed a declaratory judgment action prior to putting its power supply on the market and conceded that it did not intend to sell the supply unless the Court determined invalidity or noninfringement in favor of Sierra. The court considered whether a sufficient case or controversy existed to support such a declaratory action.

AEI’s counsel, at oral arguments, represented that AEI would not sue Sierra for its current in-house use (for design or testing) of its power supply technology. The Court found that these representations created an estoppel against AEI in future suits and thus eliminated any case or controversy for the associated actions. In reference to a second power supply technology being developed by Sierra, the Court ruled that Sierra’s efforts at developing the device were not sufficiently far along “on the date of the complaint.” Reversed-in-part, vacated-in-part, affirmed-in-part, and remanded.

Geof has more on the case.

Commentary: Declaratory judgments actions require action by both the defendant (e.g., threaten suit) and the plaintiff (e.g., arguably infringing activity) in order to be appropriate. It is interesting that the Court examined the plaintiff’s actions up to the date of filing the complaint (Sierra being far from completing its new product as of filing) but examined the defendant’s actions that occurred much later (counsel conceding at oral arguments that AEI will not file suit for in-house uses).

Necktie Inventor

necktie

When worn, Josh Maggert’s necktie appears identical to a conventional necktie. . . . Secretly, however, the necktie has a lint-brush backing. When Josh wants to remove lint from his shirt, he simply brushes the back of the tie over the offending debris. (U.S. Patent 6,170,085).

Read necktie history here.

David Johnson has written a history of the necktie. The Lemelson-MIT program provides resources for inventors. Thanks to Kevin Heller for his link to tiegate.

Proposed Amendments to 35 U.S.C. 102(f) and 103(c)

Representative Smith (R Texas) talks on the Congressional floor about three recent Bills that have passed the House and are awaiting action in the Senate. Rep. Smith recently gave a speech to the ABA IP Section discussing the bills and other IP matters.

One of the recently passed Bills is the “Cooperative Research and Technology Enhancement (CREATE).” Under the Bill’s proposed amendments, 35 U.S.C. 102(f) references will not be considered prior art or as evidence of obviousness under section 103. (Section 102(f) references show the subject matter to be patented was not invented by the one applying for the patent.)

In addition, section 103(c) would be amended so that subject matter developed by another person and prior art under 102(e) or (g) will not preclude patentability if the subject matter and the clamed invention were, “at the time of the earliest filing date for which benefit is sought . . . owned by the same person or subject to an obligation of assignment to the same person.” The new law would not be retroactively applied.

The parallel Senate Bill S.2192 was introduced by Senator Hatch (R Utah). You can read Senator Hatch’s introduction of the Bill. According to co-sponsor Senator Leahy, this Bill will circumvent the ruling in OddzOn Products, Inc. v. Just Toys, Inc. (Fed. Cir. 1997) (holding that non-public information may be used as prior art under certain circumstances), thus allowing more collaboration. Philip McGarrigle published an article in IDEA discussing the OddzOn Products. Brian Murphy disagreed with OddzOn Products in the Fordham IP Law Journal. Additionally, James Gambrell discusses the use of section 102(f)/103 prior art in the Federal Circuit Bar Journal.

Taxing Patent Donations

Parallel Bills have been introduced in the House and Senate to limit income tax deductions for charitable contributions of patents and similar property by requiring a “qualified appraisal.” S2103 H3867

Michigan State University provides some details for giving a charitable contribution of intellectual property as does giftlaw.com. Janal Kalis provides a story on changes made at the IRS regarding patent donations. According to the story, the IRS is cracking down because corporations were claiming greater donations than they were entitled to. Nipper provides more information and a link to the Intellectual Property Owners (IPO) commentary. The IPO has sent an open letter to Senator Grassley opposing the Bills.

Snippets

snippets

SnippetsTM provides a review of timely developments in intellectual property law. Here is a table of contents of the most recent issue (April 2004):

1. Anthoula Pomrening, Drafting the Technology Game Plan, Part 4: Effective Trademark Searching
2. Blair Hughes, The New Statutory Interference Bar: Should you Monitor Competitors’ Published Patents?
3. Alison Baldwin, Patent Validity Assessments: Your Guide to Avoiding the On-Sale Bar
4. Michael Greenfield and Jennifer Swartz, Claim Construction 101: Unlocking the Meaning of Preambles
5. Brian Harris, Caveat Sender: What Else is Attached to Your E-Mail?

Those interested can request a pdf version of the publication by emailing your contact info to the editor.

Monsanto Co. v. Homan McFarling (Fed. Cir. 2004)

Monsanto Co. v. Homan McFarling
DNA
McFarling replanted some ROUNDUP READY(r) soybeans that he had saved from his prior year’s crop in violation of the Technology Agreement that he signed as a condition of his purchase of the seeds from Monsanto. (U.S. Patents 5,633,435 and 5,352,605). On appeal from a summary judgment, McFarling argued that the Technology Agreement involved an unlawful misuse of Monsanto’s patents by restricting use of “god-made” second-generation seeds. The Court disagreed. Because the first-generation seeds (sold by Monsanto) were nearly identical copies to the second-generation seeds, the court found that the patent scope includes both generations. Thus, the Court rejected McFarling’s appeal and held that the Technology Agreement did not impermissibly extend Monsanto’s rights.

The Court vacated and remanded the district court’s damages award under Missouri law as an “unenforceable and invalid penalty clause.”

Andrew Hagen provides some anti-GMO comments and links. Canola Farmers may also be violating Monsanto’s patents. Here is an older article on the Roundup Ready soybean controversy, and here is another. Andrew Raff provides further commentary.

Update: Farmers in Argentina are allowed to cull seeds for replanting new crops. Apparently there is also a large black-market for GM seeds. (Thanks to Carol Nottenburg for the link).

Inland Steel Co. v. LTV Steel Co. (Fed. Cir. 2004)

Inland Steel Co. v. LTV Steel Co. and USX Corp.

The Court found that USX was a “prevailing party” on a claim before the district court, even though USX prevailed on the issue of invalidity in a different forum (a PTO reexamination). (U.S. Patents 4,421,574 and 4,483,723). Thus, USX may have a right to attorney fees and costs under 35 U.S.C. 285 and Rule 54(d) of the Federal Rules of Civil Procedure. The major indication of the status of prevailing party cited by the Court is that the case would have res judicata effect as to any claims brought against USX in the future with respect to the patent claims that were at issue in the district court case.

Reversed and remanded to determine whether the case is “exceptional” or if the court should exercise its discretion to allow or deny costs to the prevailing party.